1. Thyroid dysfunction in patients with diffuse large B-cell lymphoma receiving lenalidomide is mediated by TNF-α
- Author
-
Iams, Wade T., Hames, Megan L., Tsai, Judy P., Dahlman, Kimberly B., Talbott, Mahsa S., Richards, Kristy L., and Reddy, Nishitha M.
- Subjects
Adult ,Aged, 80 and over ,Interleukin-15 ,Male ,Adolescent ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Antineoplastic Agents ,Middle Aged ,Interleukin-12 ,Severity of Illness Index ,Article ,Thalidomide ,Antibodies, Monoclonal, Murine-Derived ,Interferon-gamma ,Hypothyroidism ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Immunologic Factors ,Female ,Lymphoma, Large B-Cell, Diffuse ,Rituximab ,Lenalidomide ,Aged - Abstract
As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced thyroid abnormalities will increase. In this study, we compared rates of therapy-induced hypothyroidism in 329 patients with diffuse large B-cell lymphoma (DLBCL) treated with conventional chemotherapy (DLBCL-c) or conventional chemotherapy plus lenalidomide (DLBCL-len). We measured serum levels of tumor necrosis factor α, interferon gamma, interleukin 6, interleukin 12, and interleukin 15 before and after treatment. We found a significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs. 1.3%), and we found a statistically significant increase in serum tumor necrosis factor α in patients with lenalidomide-induced hypothyroidism.
- Published
- 2014